IntelligentMDx, a Cambridge, MA-based maker of molecular diagnostic tests, has garnered FDA emergency use authorization for its product for detecting the H1N1 virus, the company announced today. No test has been approved for identifying H1N1, but the emergency use authorization allows the IntelligentMDx diagnostic assay to be used while the flu outbreak is still in emergency status, a state that is set to expire on April 26 of this year, the company said.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
